Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment

早前報道，中國國家藥監局批准愛文思控股的VYLOY（Zolbetuximab）用於晚期胃癌治療。

Benzinga · 01/06 14:55

- China has the highest number of cases and deaths from gastric cancer of any country worldwide1 -

- 中國是全球胃癌病例和死亡人數最多的國家1 -

- Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker expressed by 35% of Chinese patients with advanced gastric and gastroesophageal junction (GEJ) cancer2 -

- Zolbetuximab 是中國首個也是唯一一個批准用於靶向 claudin 18.2 的治療，claudin 18.2 是35%的晚期胃癌和胃食管交界癌（GEJ）中國患者所表達的生物標誌物2 -

- Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend both progression-free survival and overall survival in the Phase 3 GLOW and SPOTLIGHT trials3,4 -

- 在階段3 GLOW 和 SPOTLIGHt 試驗中，claudin 18.2 靶向單克隆抗體的治療顯著延長了無進展生存期和總體生存期3,4 -

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment

Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment

風險及免責聲明

聲明